2020
SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
Murari K, Insogna K. SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2020, 4: sun-333. PMCID: PMC7207437, DOI: 10.1210/jendso/bvaa046.1470.Peer-Reviewed Original ResearchTrabecular bone scoreBone mineral densityL-spine bone mineral densityTotal hip bone mineral densityHip bone mineral densityBone scorePhase III clinical trialsRegional bone mineral densityRenal phosphate leakCourse of treatmentHuman monoclonal antibodyConsiderable clinical relevanceSignificant increaseFGF-23Frequent siteClinical trialsMineral densityMineral metabolismBone densityDrug treatmentPhosphate leakBurosumabBMD measurementsClinical relevanceStudy subjects
1989
Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria
Insogna K, Ellison A, Burtis W, Sartori L, Lang R, Broadus A. Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria. Journal Of Urology 1989, 141: 269-273. PMID: 2913343, DOI: 10.1016/s0022-5347(17)40737-3.Peer-Reviewed Original ResearchConceptsOral phosphate therapyDihydroxyvitamin D levelsAbsorptive hypercalciuriaUrinary calciumParathyroid functionPhosphate therapyPhosphate administrationD levelsOral phosphate administrationRenal phosphate thresholdTreatment urinary calciumStudy 36 patientsPre-treatment valuesTrichlormethiazide treatmentCalcium excretionDihydroxyvitamin DBiochemical abnormalitiesSecond drugPharmacological meansStudy subjectsHypercalciuriaPatientsTherapyPer cent decreaseTreatment